Funding

Vaderis Therapeutics

Switzerland · Biotech · Enterprise software

Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia

Visit vaderis.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series B$152MDroia — Role not disclosedEQT Life Sciences — Role not disclosedGoldman Sachs Alternatives — Role not disclosedKalehua Capital — Role not disclosedMedicxi — Role not disclosedOmega Funds — Role not disclosedPerceptive Advisors — Role not disclosedTCGX — Role not disclosed

Investors

DroiaSeries BEQT Life SciencesSeries BGoldman Sachs AlternativesSeries BKalehua CapitalSeries BMedicxiSeries BOmega FundsSeries BPerceptive AdvisorsSeries BTCGXSeries B

Coverage

Aug 11, 2026Vaderis Therapeutics · Series B

Similar companies

Knowledge WorkTokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.¥4.8B · Series C debt second close
Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
Sourcesvaderis.com ↗